VSTM targets late 2026 financial self-sufficiency as it advances VS-7375 in low-grade serous ovarian cancer trials.
Verastem Oncology outlined plans to release response-rate data for VS-7375 in October, a key pipeline asset for low-grade serous ovarian cancer (LGSOC). The update follows a Q2 2026 quarter marked by commercial and pipeline progress, according to management commentary.
The company reported net product revenue growth but did not disclose specific figures. Verastem aims to achieve self-sustainability by the end of 2026, aligning with its broader strategy to expand its oncology portfolio. VS-7375 remains a focal point for near-term catalysts.
No immediate market reaction was detailed in the earnings call summary. Shares of VSTM have been volatile amid pipeline developments and commercial execution challenges.